Sciences – Earlybirds Invest https://earlybirdsinvest.com Latest Crypto News Sat, 22 Mar 2025 00:51:30 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.9 https://i0.wp.com/earlybirdsinvest.com/wp-content/uploads/2024/12/cropped-New-Project-2024-12-17T235703.455.png?fit=32%2C32&ssl=1 Sciences – Earlybirds Invest https://earlybirdsinvest.com 32 32 240146708 Atai Life Sciences Bets $5 Million on Bitcoin to Survive the Funding Freeze https://earlybirdsinvest.com/atai-life-sciences-bets-5-million-on-bitcoin-to-survive-the-funding-freeze/ https://earlybirdsinvest.com/atai-life-sciences-bets-5-million-on-bitcoin-to-survive-the-funding-freeze/#respond Sat, 22 Mar 2025 00:51:30 +0000 https://earlybirdsinvest.com/atai-life-sciences-bets-5-million-on-bitcoin-to-survive-the-funding-freeze/

Atai Life Sciences, a biopharma company listed on NASDAQ, has decided to invest $5 million in Bitcoin
BTC


$83,926.94

.

The company’s founder and chairman, Christian Angermayer, explained the decision in an X post on March 20. He said that developing new treatments takes years and requires a steady stream of funding. However, many firms are running out of money while waiting for regulatory approval.

Angermayer pointed out that most companies store their cash in low-return accounts, but it may not be enough to protect against inflation. He believes it’s time for biotech firms to consider other ways to manage their finances—like adding Bitcoin to their reserves.

What is Basic Attention Token (BAT)? Brave Browser EASILY Explained

Did you know?

Want to get smarter & wealthier with crypto?

Subscribe – We publish new crypto explainer videos every week!

What is Basic Attention Token (BAT)? Brave Browser EASILY Explained

What is Basic Attention Token (BAT)? Brave Browser EASILY Explained
What is Basic Attention Token (BAT)? Brave Browser EASILY Explained

Atai is currently working on treatments that use substances such as DMT and MDMA to address mental health conditions. While the research is ongoing, the company also needs to make sure it has enough cash to continue operating through 2027.

Angermayer said that the Bitcoin purchase is mostly a way to guard against inflation in the long term. In the short term, it also helps to spread risk by not keeping all funds in the same types of assets.

At current market rates, the company’s $5 million investment would buy just over 59 BTC. This would place Atai among the top 60 public companies holding Bitcoin, according to Bitbo, a real-time Bitcoin dashboard.

On March 14, Trump Media & Technology Group announced the launch of a $179 million special-purpose acquisition company (SPAC) named Renatus Tactical. What is the company’s goal? Read the full story.

Aaron S. Editor-In-Chief

Having completed a Master’s degree in Economics, Politics, and Cultures of the East Asia region, Aaron has written scientific papers analyzing the differences between Western and Collective forms of capitalism in the post-World War II era.
With close to a decade of experience in the FinTech industry, Aaron understands all of the biggest issues and struggles that crypto enthusiasts face. He’s a passionate analyst who is concerned with data-driven and fact-based content, as well as that which speaks to both Web3 natives and industry newcomers.
Aaron is the go-to person for everything and anything related to digital currencies. With a huge passion for blockchain & Web3 education, Aaron strives to transform the space as we know it, and make it more approachable to complete beginners.
Aaron has been quoted by multiple established outlets, and is a published author himself. Even during his free time, he enjoys researching the market trends, and looking for the next supernova.

]]> https://earlybirdsinvest.com/atai-life-sciences-bets-5-million-on-bitcoin-to-survive-the-funding-freeze/feed/ 0 26498 Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy https://earlybirdsinvest.com/nasdaq-listed-biotech-firm-atai-life-sciences-to-launch-bitcoin-treasury-strategy/ https://earlybirdsinvest.com/nasdaq-listed-biotech-firm-atai-life-sciences-to-launch-bitcoin-treasury-strategy/#respond Fri, 21 Mar 2025 07:20:50 +0000 https://earlybirdsinvest.com/nasdaq-listed-biotech-firm-atai-life-sciences-to-launch-bitcoin-treasury-strategy/

Atai Life Sciences, a Germany-based biopharmaceutical company, has become the latest publicly traded firm to adopt a Bitcoin treasury strategy.

The Nasdaq-listed company, chaired by entrepreneur Christian Angermayer, announced plans to allocate a portion of its cash reserves into Bitcoin (BTC) as a hedge against inflation and a means of capital optimization amid challenging market conditions.

In a statement published on Substack, Angermayer explained the rationale behind the move, citing persistent inflation, rising interest rates, and volatile funding environments as driving factors.

“Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success?” Angermayer wrote, referring to the financial pressure many biotech companies are currently facing.

Atai Life Sciences to Start with a $5M Investment

The firm will initially invest $5 million into Bitcoin while maintaining a diversified reserve of cash, short-term securities, and public equities to fund operations through 2027.

At current prices, the investment would give Atai a holding of just over 59 BTC, placing it among the top 60 public companies holding Bitcoin, according to Bitbo data.

Atai joins a growing list of medical and biotech firms adopting crypto treasury strategies.

Quantum BioPharma recently expanded its BTC holdings to $3.5 million, while Semler Scientific has accumulated over 3,190 BTC since May 2023.

Others like Hoth Therapeutics, Acurx Pharmaceuticals, and Enlivex Therapeutics have each disclosed $1 million Bitcoin purchases.

Angermayer emphasized that the Bitcoin allocation is primarily a long-term hedge against inflation, but also serves as a short-term diversification strategy.

While acknowledging BTC’s price volatility, he stated that the firm’s core operational reserves would remain in traditional assets to ensure stability.

Atai’s share price briefly spiked on March 20 following the announcement, reaching $1.47 in early trading before closing at $1.37, down 1.44% for the day.

The stock has fallen nearly 93% since its 2021 public debut but remains up 3% year-to-date.

Bitcoin Remains Under Pressure

Bitcoin, meanwhile, has been under pressure amid wider market uncertainty.

After briefly surpassing $87,000, it has retreated to around $83,900, reflecting a 1% drop over the past 24 hours.

As reported, Bitcoin’s futures market has recently undergone a significant deleveraging event, with $10 billion in open interest wiped out in just three weeks, according to onchain analytics platform CryptoQuant.

The firm revealed that Bitcoin derivatives traders have shifted towards a risk-off stance since BTC/USD reached all-time highs in mid-January.

Open interest (OI) across major crypto exchanges peaked at $33 billion on January 17.

However, from February 20 to March 4, OI plummeted by $10 billion, signaling a broad market correction.

CryptoQuant contributor Darkfost described the decline as a “natural market reset”, emphasizing that past deleveraging events have historically paved the way for bullish continuations.

The post Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy appeared first on Cryptonews.

]]> https://earlybirdsinvest.com/nasdaq-listed-biotech-firm-atai-life-sciences-to-launch-bitcoin-treasury-strategy/feed/ 0 26364